eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2012
vol. 37
 
Share:
Share:

Experimental immunology
The influence of sterilized and non-sterilized amniotic dressings on the proliferation of endothelial cells in vitro

Piotr Skopiński
,
Robert Zdanowski
,
Tomasz Grzela
,
Artur Kamiński
,
Sławomir Lewicki
,
Ewa Skopińska-Różewska
,
Wanda Stankiewicz

(Centr Eur J Immunol 2012; 37 (2): 114-118)
Online publish date: 2012/05/22
Article file
Get citation
 
 

Introduction



An often problem with tissue-engineered skin is delayed vascularization. It is important to know, how biological dressings might influence angiogenesis, and how preservation of these materials may change this effect. Extensive skin loss and chronic wounds present a significant problem to the clinician. Then, a number of approaches to use various natural and synthetic dressings have been developed [1-6]. An important component of tissue engineering (TE) is supporting scaffold (matrix upon which cells and tissues grow). The amniotic membrane (AM) is an ideal candidate for creating scaffolds used in tissue engineering [7-12].

The procedure of obtaining amniotic membrane even at the time of cesarean section does not guarantee a complete sterility and its proper sterilization is fundamental. Accordingly, various procedures of the preparation, sterilization and long-term storage of AM samples have been developed and the effects of these procedures on the total protein and growth factors content were described. Even preserved human AM expresses mRNAs for a number of growth factors and contains several growth factors proteins enhancing epithelialization and suppressing inflammation, what is beneficial for wound healing [13-23]. However, it was also reported that human AM secretes and releases angiogenesis inhibitors: tissue inhibitor of metalloproteinases (TIMP 2), pigment epithelium-derived factor (PEDF) and endostatin [24-29].

Conditioned culture medium of AM suppresses neovascularization induced by basic fibroblast growth factor (bFGF), inhibiting the migration and growth of endothelial cells. This unwanted effect of AM may create some limitation of its use in tissue engineering, as vascularization in healing wound is essential for successful tissue repair.

On the other hand, this unwanted effect appears to be beneficial in some other clinical situations, for example in ophthalmology, where AM may be applicable for treatment of corneal diseases with neovascularization.

The aim of our study was to evaluate the effect of routinely used in Central Tissue Bank sterilization method (irradiation 35 kGy) of deeply frozen human amnion, on the ability of this tissue to influence proliferation of endothelial cells in in vitro cell culture.

Material and methods

Amnion samples



Experiments were performed on already prepared, non-sterilized or radiation-sterilized amnion dressings, prepared routinely by the Department of Transplantology and Central Tissue Bank of Biostructure Center, the Medical University of Warsaw [30]. The procedure for collection and preparation of dressings, which meet all the requirements of biological materials intended for clinical application, is covered by legislative regulations, together with appropriate approval of the local ethics committee. Sterilization of tissue samples was performed after their deep freezing, on dry ice, in

a 10 MeV electron accelerator with the dose of 35 kGy. Samples were stored at –70°C until their further use.



Alamar Blue assay for HECa10 cell proliferation [31]



HECa10 mouse endothelial cell line was supplied by Laboratory of Glycobiology and Cell Interactions, Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, Wrocław. Cells were maintained in 75 cm2 (BD Bioscience) culture flasks under standard culture conditions of 5% CO2 at 37°C with medium renewal every 2-3 days. Cells which in log phase growth stage were harvested (Accutase, PAA) and cell count determined, suspended (4 × 104 cells/ml) in culture medium (DMEM, 4.5 g/ml glucose (PAA) with L-glutamine and antibiotics), and then seeded into wells of a 24-well plates (1 ml per well). Next, plates were incubated at standard culture conditions of 5% CO2 in air at 37°C. After an hour the inserts (0.4 µm, BD) were imposed on each well and 100 µl of FBS (PAA) or small pieces (0.01 ±0.002 g) of the radiation-sterilized or non-sterilized AM were added to the upper chamber (to the inserts). Also, 100 µl of the homogenate (0.02 γ of the sterilized or non-sterilized AM in 1 ml of FBS free DMEM; mechanically homogenized, incubated 1 h under standard culture conditions and centrifuged at 1000 G) was added to inserts. As a negative control a cells suspended in the DMEM medium (without FBS) were used. Next the plates were returned to the incubator.

After a 20-h exposure medium and inserts with tissues were discarded and fresh FBS free DMEM medium (1 ml) with Alamar Blue (AB, 100 µl, 1/10 v/v) was added directly to the wells. Cells were incubated for 5 h at 37°C and 5% CO2. After this time, fluorescence was measured (FLUOstar Omega, BMG Labtech) at excitation 544 nm and emission 590 nm.

The results are shown as the relative fluorescence units (RFU) of treated (with tissues) and control cells (without FBS, or with 10% of FBS). Because the culture medium was not changed during last period, the results are a cumulative value.



Statistical evaluation of the results



The results obtained from 36 cell cultures were analyzed. Statistical analysis was done by 2-way ANOVA and the significance of differences between the groups was verified by Bonferroni post-test (Graph Pad Prism software).

Results and discussion



Alamar Blue assay of cells proliferation has been shown to be an alternative to the 3H-thymidine incorporation assay [30]. Previously, in experiments with endothelial cells cultures exposed to 900 MHz electromagnetic field we obtained comparable results by these two methods [32].

The results of experiments with amniotic membrane fragments are presented on Fig. 1. Non-sterilized amnion significantly stimulated (p < 0.05) endothelial cells proliferation. In contrast, sterilized amnion samples significantly diminished Alamar Blue reduction (p < 0.001).

The results of experiments performed with AM homogenate are presented on Fig. 2. No difference was seen between the control fluorescence values (cultures with 10% of FBS) and cultures with non-sterilized amnion tissue homogenate. Significantly lower EC proliferation was observed in cell cultures containing homogenate of radiation-sterilized AM (p < 0.001).

Then, the results of our present study showed the existence of some angiostimulatory activity in AM before its sterilization, probably connected with growth factors of epithelial origin [12, 18, 23]. Sterilization, however, recovers strong inhibitory activity visible both in cultures with sterilized AM fragments and in cultures with sterilized AM homogenate.

Such inhibitory activity might be dependent on the presence of previously described endogenous anti-angiogenic agents (TIMPs, PEDF, endostatin) as well as on the presence of hyaluronic acid. It has been reported that hyaluronic acid glycans and oligosaccharide exert different effects on the biological function of the vascular endothelial cell, resulting in altered regulation of angiogenesis [33].

Sterilized AM is often used in ophthalmological surgery. Amniotic membrane transplantation has been shown to be effective in the management of ocular surface pathologies, also of inflammatory origin [34, 35]. Amniotic membrane transplantation can be a first – step procedure for ocular surface reconstruction in ocular-cicatricial pemphigoid [36], can be used as an efficient and safe treatment for symptomatic bullous keratopathy, when penetrating keratoplasty is not available [37] and to repair of necrotizing scleritis [38]. Amniotic membrane implantation was described to reduce extraocular muscle adhesions to a titanium implant placed during prior surgery [39]. Amniotic cell culture supernatant, which contains potent inhibitors of angiogenesis, may be applicable for treatment of corneal diseases with neovascularization [40]. Finally, AM may be used as a drug reservoir, slowly releasing antibiotic, especially in infectious keratitis [41]. Anti-inflammatory effect of AM is connected with suppression of inflammatory cytokine production, inhibition of proliferation and induction of apoptosis in various cell populations, among them, peripheral blood mononuclear cells [42].

Other applications of amnion dressings comprise local treatment of chronic wounds and traumatic skin defects [43, 44], venous ulcers [45-47], burns [48, 49] and for preventing prolonged air leakage after thoracic surgery [50].

It is plausible, that in the applications performed from non-ophthalmic indications, the results would be even better by combining amniotic dressing with angio- and immunostimulators, (growth factors and their sources, stimulatory antibiotics and other antimicrobial substances, immunostimulators and stimulators of angiogenesis of natural origin, and some physical methods [32, 51-59]. 

References



 1. Cerqueira MT, Marques AP, Reis RL (2012): Using stem cells in skin regeneration: possibilities and reality. Stem Cells Dev (Epub ahead of print).

 2. Vishnubalaji R, Manikandan M, Al-Nbaheen M, et al. (2012): In vitro differentiation of human skin-derived multipotent stromal cells into putative endothelial-like cells. BMC Dev Biol 12: 7.

 3. Nomi M, Atala A, Coppi PD, Soker S (2002): Principals of neovascularization for tissue engineering. Mol Aspects Med 23: 463-483.

 4. Chern PL, Baum CL, Arpey CJ (2009): Biologic dressings: current applications and limitations in dermatologic surgery. Dermatol Surg 35: 891-906.

 5. Geckil H, Xu F, Zhang X, et al. (2010): Engineering hydrogels as extracellular matrix mimics. Nanomedicine (Lond) 5: 469-484.

 6. Burdick JA, Prestwich GD (2011): Hyaluronic acid hydrogels for biomedical applications. Adv Mater 23: H41-56.

 7. Gruss JS, Jirsch DW (1978): Human amniotic membrane: a versatile wound dressing. Can Med Assoc J 118: 1237-1254.

 8. Tsai SH, Liu YW, Tang WC, et al. (2007): Characterization of porcine arterial endothelial cells cultured on amniotic membrane, a potential matrix for vascular tissue engineering. Biochem Biophys Res Commun 357: 984-990.

 9. Niknejad H, Peirovi H, Jorjani M, et al. (2008): Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88-99.

10. Pessolato AG, Martins Ddos S, Ambrósio CE, et al. (2011): Propolis and amnion reepithelialise sedond-degree burns in rats. Burns 37: 1192-1201.

11. Andonovska D, Dzokic G, Spasevska L, et al. (2008): The advantages of the application of amnion membrane in the treatment of burns. Prilozi 29: 183-198.

12. Ji SZ, Xiao SC, Luo PF, et al. (2011): An epidermal stem cells niche microenvironment created by engineered human amniotic membrane. Biomaterials 32: 7801-7811.

13. Dziedzic-Goclawska A, Kaminski A, Uhrynowska-Tyszkiewicz I, Stachowicz W (2005): Irradiation as a safety procedure in tissue banking. Cell Tissue Bank 6: 201-219.

14. Riau AK, Beuerman RW, Lim LS, Mehta JS (2010): Preservation, sterilization and de-epithelialization of human amniotic membrane for use in ocular surface reconstruction. Biomaterials 31: 216-225.

15. Nakamura T, Yoshitani M, Rigby H, et al. (2004): Sterilized, freeze-dried amniotic membrane: a useful substrate for ocular surface reconstruction. Invest Ophthalmol Vis Sci 45: 93-99.

16. Singh R, Purohit S, Chacharkar MP, et al. (2007): Microbiological safety and clinical efficacy of radiation-sterilized amniotic membranes for treatment of second-degree burns. Burns 33: 505-510.

17. Thomasen H, Pauklin M, Steuhl KP, Meller D (2009): Comparison of cryopreserved and air-dried human amniotic membrane for ophthalmologic applications. Graefes Arch Clin Exp Ophthalmol 247: 1691-1700.

18. Koizumi NJ, Inatomi TJ, Sotozono CJ, et al. (2000): Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res 20: 173-177.

19. Niknejad H, Deihim T, Solati-Hashjin M, Peirovi H (2011): The effects of preservation procedures on amniotic membrane’s ability to serve as a substrate for cultivation of endothelial cells. Cryobiology 63: 145-151.

20. Russo A, Bonci P, Bonci P (2011): The effects of different preservation processes on the total protein and growth factors content in a new biological product developed from human amniotic membrane. Cell Tissue Bank (Epub ahead of print).

21. Wolbank S, Hildner F, Redl H, et al. (2009): Impact of human amniotic membrane preparation on release of angiogenic factors. J Tissue Eng Regen Med 3: 651-654.

22. Koh JW, Shin YJ, Oh JY, et al. (2007): The expression of TIMPs in cryo-preserved and freeze-dried amniotic membrane. Curr Eye Res 32: 611-616.

23. Litwiniuk M, Bikowska B, Niderla-Bieliska J, et al (2011): High molecular weight hyaluronan and stroma-embedded factors of radiation-sterilized amniotic membrane stimulate proliferation of HaCaT cell line in vitro. Centr Eur J Immunol 36: 205-211.

24. Jiang A, Li C, Gao Y, et al. (2006): In vivo and in vitro inhibitory effect of amniotic extraction on neovascularization. Cornea 25 (10 Suppl 1): S36-40.

25. Ma X, Li J (2005): Corneal neovascularization suppressed by TIMP 2 released from human amniotic membranes. Yan Ke Xue Bao 21: 56-61.

26. Shao C, Sima J, Zhang SX, et al. (2004): Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci 45: 1758-1762.

27. Tombran-Tink J (2005): The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci 10: 2131-2149.

28. Marciniak K, Butwicka A, Nowak JZ (2006): PEDF: an endogenous factor displaying potent neuroprotective, neurotrophic and anti-angiogenic activity. Postepy Hig Med Dosw 60: 387-396.

29. Ma DH, Yao JY, Yeh LK, et al. (2004): In vitro antiangiogenic activity in ex vivo expanded human limbocorneal epithelial cells cultivated on human amniotic membrane. Invest Ophthalmol Vis Sci 45: 2586-2595.

30. Tyszkiewicz JT, Uhrynowska-Tyszkiewicz IA, Kaminski A, Dziedzic-Goclawska A (1999): Amnion allografts prepared in the Central Tissue Bank in Warsaw. Ann Transplant 4: 85-90.

31. Al-Nasiry S, Geusens N, Hanssens M, et al. (2007): The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 22: 1304-1309.

32. Stankiewicz W, Zdanowski R, Skopińska-Różewska E, et al. (2011): The effect of 900 MHz microwave GSM signal on the proliferation of endothelial cells in vitro. Centr Eur J Immunol 36: 215-219.

33. Mo W, Yang C, Liu Y, et al. (2011): The influence of hyaluronic acid on vascular endothelial cell proliferation and the relationship with ezrin/merlin expression. Acta Biochim Biophys Sin (Shanghai) 43: 930-939.

34. Thatte S (2011): Amniotic membrane transplantation: an option for ocular surface disorders. Oman J Ophthalmol 4: 67-72.

35. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K (2001): Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea 20: 408-413.

36. Barabino S, Rolando M, Bentivoglio G, et al. (2003): Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid. Ophthalmology 110: 474-480.

37. Georgiadis NS, Ziakas NG, Boboridis KG, et al. (2008): Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. Clin Experiment Ophthalmol 36: 130-135.

38. Lazzaro DR (2010): Repair of necrotizing scleritis in ulcerative colitis with processed pericardium and a Prokera amniotic membrane graft. Eye Contact Lens 36: 60-61.

39. Mehendale RA, Dagi LR (2011): Amniotic membrane implantation to reduce extraocular muscle adhesions to a titanium implant. J AAPOS 15: 404-406.

40. Kobayashi N, Kabuyama Y, Sasaki S, et al. (2002): Suppression of corneal neovascularization by culture supernatant of human amniotic cells. Cornea 21: 62-67.

41. Resch MD, Resch BE, Csizmazia E, et al. (2011): Drug reservoir function of human amniotic membrane. J Ocul Pharmacol Ther 27: 323-326.

42. Garfias Y, Zaga-Clavellina V, Vadillo-Ortega F, et al. (2011): Amniotic membrane is an immunosuppressor of peripheral blood mononuclear cells. Immunol Invest 40: 183-196.

43. Skórkowska-Telichowska K, Czemplik M, Kulma A, Szopa J (2011): The local treatment and available dressings designed for chronic wounds. J Am Acad Dermatol (Epub ahead of print).

44. Fan W, Yang Z, Luo J, et al. (2006): A comparative study on acellular small intestinal submucosa and acellular amnion as dressings for traumatic skin defects. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20: 155-160.

45. Gutierrez-Moreno S, Alsina-Gibert M, Sampietro-Colom L, et al. (2011): Cost-benefit analysis of amniotic membrane transplantation for venous ulcers of the legs that are refractory to conventional treatment. Actas Dermosifiliogr 102: 284-288.

46. Tauzin H, Humbert P, Viennet C, et al. (2011): Human amniotic membrane in the management of chronic venous leg ulcers. Ann Dermatol Venereol 138: 572-579.

47. Maggio G, Armenio A, Ruccia F, et al. (2011): A new protocol for the treatment of the chronic venous ulcers of the lower limb. Clin Exp Med 12: 55-60.

48. Ley-Chávez E, Martínez-Pardo ME, Roman R, et al. (2003): Application of biological dressings from radiosterilized amnios with cobalt 60 and serologic studies on the handling of burns in pediatric patients. Ann Transplant 8: 46-49.

49. Singh R, Chacharkar MP (2011): Dried gamma-irradiated amniotic membrane as dressing in burn wound care. J Tissue Viability 20: 49-54.

50. Zmijewski M, Pietraszek A (2005): The application of deep-frozen and radiation-sterilized human amnion as a biological dressing to prevent prolonged air leakage in thoracic surgery. Ann Transplant 10: 17-20.

51. Radomska-Leśniewska DM, Skopińska-Różewska E, Malejczyk J (2010): The effect of clindamycin and lincomycin on angiogenic activity of human blood mononuclear cells. Centr Eur J Immunol 35: 217-223.

52. Jaguś P, Proczka R, Chorostowska-Wynimko J (2009): Differential regulation of endothelial cells proliferative and proangiogenic activity by sera from patients with lower limb ischemia. Centr Eur J Immunol 34: 239-242.

53. Gibka J, Skopińska-Różewska E, Wasiutyński A, et al. (2009): The effect of 4-undecanone and its derivatives on cellular and humoral immunity and tumor growth in mice. Centr Eur

J Immunol 34: 29-34.

54. Gibka J, Kunicka-Styczyńska A, Gliński M (2009): Antimicrobial activity of undecan-3-one, undecan-3-ol and undec-3-yl acetate. Centr Eur J Immunol 34: 154-157.

55. Warnawin E, Burakowski T, Gajewski M, et al. (2005): Preservation of chondrogenic potential of mesenchymal stem cells isolated from osteoarthritic patients during proliferation in response to platelet-derived growth factor (PDGF). Centr Eur J Immunol 30: 26-31.

56. Hartwich M (2010): The importance of immunological studies on Rhodiola rosea in the new effective and safe herbal drug discovery. Centr Eur J Immunol 35: 263-266.

57. Sierosławska A, Rymuszka A, Siwicki AK (2008): Effects of chloramphenicol and ciprofloxacin on the selected functions of rabbit phagocytic cells. Centr Eur J Immunol 33: 43-46.

58. Szymańska-Czerwińska M, Bednarek Z, Zdzisińska B, Kandefer-Szerszen M (2009): Effect of tylosin and prebiotics on the level of cytokines and lymphocyte immunophenotyping parameters in calves. Centr Eur J Immunol 34: 1-7.

59. Skopińska-Różewska E, Strzelecka H, Wasiutynski A, et al. (2008): Aqueous and hydro-alcoholic extracts of Echinacea purpurea as traditional herbal remedies with immunotropic activity. Centr Eur J Immunol 33: 75-78.
Copyright: © 2012 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.